High Expression Due to Fusion in Therapy-related Acute Myeloid Leukemia: Description of the First Pediatric Case

Overview

Journal Hemasphere

Publisher Wiley

Specialty Hematology

Date 2020 Nov 9

PMID 33163906

Citations 3

Authors

Mariella DAngio

Grazia Fazio

Andrea Grioni

Sonia Palamini

Simona Sala

Marta Galbiati

Andrea Biondi

Adriana Balduzzi

Carmelo Rizzari

Giovanni Cazzaniga

Affiliations

Soon will be listed here.

Citing Articles

EVI1-mediated Programming of Normal and Malignant Hematopoiesis.

Lux S, Milsom M Hemasphere. 2023; 7(10):e959.

PMID: 37810550 PMC: 10553128. DOI: 10.1097/HS9.0000000000000959.

3q26.2/ Rearrangements by Pericentric Inv(3): Diagnostic Challenges and Clinicopathologic Features.

Tang Z, Wang W, Yang S, El Achi H, Fang H, Nahmod K Cancers (Basel). 2023; 15(2).

PMID: 36672407 PMC: 9856433. DOI: 10.3390/cancers15020458.

The retinoic acid receptor co-factor NRIP1 is uniquely upregulated and represents a therapeutic target in acute myeloid leukemia with chromosome 3q rearrangements.

Grasedieck S, Cabantog A, MacPhee L, Im J, Ruess C, Demir B Haematologica. 2021; 107(8):1758-1772.

PMID: 34854277 PMC: 9335095. DOI: 10.3324/haematol.2021.276048.

References

Balgobind B, Lugthart S, Hollink I, Arentsen-Peters S, van Wering E, de Graaf S . EVI1 overexpression in distinct subtypes of pediatric acute myeloid leukemia. Leukemia. 2010; 24(5):942-9. DOI: 10.1038/leu.2010.47. View

Li F, He W, Geng R, Xie X . Myeloid leukemia with high EVI1 expression is sensitive to 5-aza-2'-deoxycytidine by targeting miR-9. Clin Transl Oncol. 2019; 22(1):137-143. DOI: 10.1007/s12094-019-02121-y. View

Haferlach C, Bacher U, Grossmann V, Schindela S, Zenger M, Kohlmann A . Three novel cytogenetically cryptic EVI1 rearrangements associated with increased EVI1 expression and poor prognosis identified in 27 acute myeloid leukemia cases. Genes Chromosomes Cancer. 2012; 51(12):1079-85. DOI: 10.1002/gcc.21992. View

Barjesteh van Waalwijk van Doorn-Khosrovani S, Erpelinck C, van Putten W, Valk P, Hack R, Slater R . High EVI1 expression predicts poor survival in acute myeloid leukemia: a study of 319 de novo AML patients. Blood. 2002; 101(3):837-45. DOI: 10.1182/blood-2002-05-1459. View

Wanquet A, Prebet T, Berthon C, Sebert M, Roux C, Kulasekararaj A . Azacitidine treatment for patients with myelodysplastic syndrome and acute myeloid leukemia with chromosome 3q abnormalities. Am J Hematol. 2015; 90(10):859-63. DOI: 10.1002/ajh.24099. View

Brown C, Youlden D, Aitken J, Moore A . Therapy-related acute myeloid leukemia following treatment for cancer in childhood: A population-based registry study. Pediatr Blood Cancer. 2018; 65(12):e27410. DOI: 10.1002/pbc.27410. View

Nucifora G, Laricchia-Robbio L, Senyuk V . EVI1 and hematopoietic disorders: history and perspectives. Gene. 2005; 368:1-11. DOI: 10.1016/j.gene.2005.09.020. View

Grioni A, Fazio G, Rigamonti S, Bystry V, Daniele G, Dostalova Z . A Simple RNA Target Capture NGS Strategy for Fusion Genes Assessment in the Diagnostics of Pediatric B-cell Acute Lymphoblastic Leukemia. Hemasphere. 2019; 3(3):e250. PMC: 6746019. DOI: 10.1097/HS9.0000000000000250. View

Bindels E, Havermans M, Lugthart S, Erpelinck C, Wocjtowicz E, Krivtsov A . EVI1 is critical for the pathogenesis of a subset of MLL-AF9-rearranged AMLs. Blood. 2012; 119(24):5838-49. PMC: 3382941. DOI: 10.1182/blood-2011-11-393827. View

10.

Canaani J, Labopin M, Itala-Remes M, Blaise D, Socie G, Forcade E . Prognostic significance of recurring chromosomal abnormalities in transplanted patients with acute myeloid leukemia. Leukemia. 2019; 33(8):1944-1952. DOI: 10.1038/s41375-019-0439-3. View

11.

Glass C, Wilson M, Gonzalez R, Zhang Y, Perkins A . The role of EVI1 in myeloid malignancies. Blood Cells Mol Dis. 2014; 53(1-2):67-76. DOI: 10.1016/j.bcmd.2014.01.002. View

12.

De Braekeleer M, Le Bris M, De Braekeleer E, Basinko A, Morel F, Douet-Guilbert N . 3q26/EVI1 rearrangements in myeloid hemopathies: a cytogenetic review. Future Oncol. 2015; 11(11):1675-86. DOI: 10.2217/fon.15.64. View

13.

Lugthart S, Groschel S, Beverloo H, Kayser S, Valk P, van Zelderen-Bhola S . Clinical, molecular, and prognostic significance of WHO type inv(3)(q21q26.2)/t(3;3)(q21;q26.2) and various other 3q abnormalities in acute myeloid leukemia. J Clin Oncol. 2010; 28(24):3890-8. DOI: 10.1200/JCO.2010.29.2771. View

14.

Mittal N, Li L, Sheng Y, Hu C, Li F, Zhu T . A critical role of epigenetic inactivation of miR-9 in EVI1 pediatric AML. Mol Cancer. 2019; 18(1):30. PMC: 6391809. DOI: 10.1186/s12943-019-0952-z. View

15.

Bobadilla D, Enriquez E, Alvarez G, Gaytan P, Smith D, Slovak M . An interphase fluorescence in situ hybridisation assay for the detection of 3q26.2/EVI1 rearrangements in myeloid malignancies. Br J Haematol. 2007; 136(6):806-13. DOI: 10.1111/j.1365-2141.2007.06505.x. View